University Hospitals Cleveland Medical Center

uhhospitals.org

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

286

Active

45

Phase 3

23

Total enrollment

372,891

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Estradiol—————1
Bupivacain 0.625%/Fentanyl 2mcg/ml—————1
Valtoco Nasal Product—————1
Intra-articular—————1
Deutetrabenazine Oral—————1
IV Magnesium Sulfate—————1
Ustekinumab————2
Milk thistle—————1
Memantine————2
Autologous Mesenchymal Stem Cells—————1
Dexmedetomidine————2
Ropivacaine—————1
Iohexol—————1

Next readouts

  • 2026-07
  • 2026-08-31
  • 2026-09-30
  • 2026-12-31
  • 2026-12-31
  • 2027-01-25
  • 2027-04-01
  • 2027-08-11
  • 2027-10-01
  • 2028-05

Top conditions

  • Bipolar Disorder20
  • Sickle Cell Disease8
  • Cystic Fibrosis8
  • Psoriasis7
  • Inflammation5
  • HIV Infections5
  • Postoperative Pain5
  • Diverticulitis4

Frequently asked questions about University Hospitals Cleveland Medical Center

How many clinical trials does University Hospitals Cleveland Medical Center have on ClinicalTrials.gov?
University Hospitals Cleveland Medical Center is listed as the lead sponsor on 286 clinical trials in ClinicalTrials.gov, 45 of which are currently active (recruiting, enrolling, or ongoing).
How many of University Hospitals Cleveland Medical Center's trials are in Phase 3?
23 of University Hospitals Cleveland Medical Center's trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does University Hospitals Cleveland Medical Center focus on?
University Hospitals Cleveland Medical Center's most-studied conditions on ClinicalTrials.gov are Bipolar Disorder, Sickle Cell Disease, Cystic Fibrosis, Psoriasis, Inflammation.
When are University Hospitals Cleveland Medical Center's next clinical trial readouts?
University Hospitals Cleveland Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Impact of Mesenchymal Stem Cells in Knee Osteoarthritis”, expected around 2026-07.